{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:29:51Z","timestamp":1787624991136,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1038\/s41375-023-02069-7","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T03:01:56Z","timestamp":1698980516000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-0756","authenticated-orcid":false,"given":"Hassan","family":"Awada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surui","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Cronin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba","family":"Ba Aqeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya Mariam","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Salman","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kouides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-8248","authenticated-orcid":false,"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Elshoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"2069_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, H\u00e4nel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18. https:\/\/doi.org\/10.1186\/s13045-016-0242-9.","journal-title":"J Hematol Oncol."},{"key":"2069_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","volume":"12","author":"K Martin","year":"2017","unstructured":"Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malig Rep. 2017;12:389\u201396. https:\/\/doi.org\/10.1007\/s11899-017-0400-3.","journal-title":"Curr Hematol Malig Rep"},{"key":"2069_CR3","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176\u201384. https:\/\/doi.org\/10.1182\/blood-2013-03-460154.","journal-title":"Blood"},{"key":"2069_CR4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY, et al. Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med. 2018;168:317\u201325. https:\/\/doi.org\/10.7326\/M17-0028.","journal-title":"Ann Intern Med."},{"key":"2069_CR5","doi-asserted-by":"publisher","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","volume":"120","author":"T Barbui","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128\u201333. https:\/\/doi.org\/10.1182\/blood-2012-07-444067.","journal-title":"Blood."},{"key":"2069_CR6","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x.","journal-title":"J Thromb Haemost"},{"key":"2069_CR7","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","volume":"26","author":"A Carobbio","year":"2008","unstructured":"Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26:2732\u20136. https:\/\/doi.org\/10.1200\/JCO.2007.15.3569.","journal-title":"J Clin Oncol."},{"key":"2069_CR8","doi-asserted-by":"publisher","first-page":"107602962093887","DOI":"10.1177\/1076029620938874","volume":"26","author":"N Yada","year":"2020","unstructured":"Yada N, Yoshimoto K, Kawashima H, Yoneima R, Nishimura N, Tai Y, et al. Plasma level of von willebrand factor propeptide at diagnosis: a marker of subsequent renal dysfunction in autoimmune rheumatic diseases. Clin Appl Thromb Hemost. 2020;26:1076029620938874. https:\/\/doi.org\/10.1177\/1076029620938874.","journal-title":"Clin Appl Thromb Hemost."},{"key":"2069_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2019.00085","volume":"10","author":"M Mussbacher","year":"2019","unstructured":"Mussbacher M, Salzmann M, Brostjan C, Hoesel B, Schoergenhofer C, Datler H, et al. Cell type-specific roles of NF-\u03baB linking inflammation and thrombosis. Front Immunol. 2019;10:85. https:\/\/doi.org\/10.3389\/fimmu.2019.00085.","journal-title":"Front Immunol."},{"key":"2069_CR10","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1408617.","journal-title":"N Engl J Med."},{"key":"2069_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1701719.","journal-title":"N Engl J Med."},{"key":"2069_CR12","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature15252","volume":"525","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389\u201393. https:\/\/doi.org\/10.1038\/nature15252.","journal-title":"Nature."},{"key":"2069_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842\u20137. https:\/\/doi.org\/10.1126\/science.aag1381.","journal-title":"Science."},{"key":"2069_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0107-2","volume":"8","author":"P Savola","year":"2018","unstructured":"Savola P, Lundgren S, Keranen MAI, Almusa H, Ellonen P, Leirisalo-Repo M, et al. Clonal hematopoiesis in patients with rheumatoid arthritis. Blood Cancer J. 2018;8:69. https:\/\/doi.org\/10.1038\/s41408-018-0107-2.","journal-title":"Blood Cancer J."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02069-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02069-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T14:04:27Z","timestamp":1704809067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02069-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2069"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02069-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EAG discloses conflicts of interest including direct fees for advisory services from: AbbVie, Alexion Pharmaceuticals, Apellis, Celgene\/BMS, CTI Biopharma, Genentech, Novartis, Picnic Health, Takeda Oncology, Taiho Oncology, Research Funding to Roswell Park from Astex Pharmaceuticals, AstraZeneca Rare Disease, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Blueprint Medicines, Genentech Inc. and CME\/Honoraria payments from Physicians Educational Resource, MediCom Worldwide, American Society of Hematology, AAMDS International Foundation, MDS International Foundation, and the Vera & Joseph Dresner Foundation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}